HeartBeam Expands Board with CEO Robert Eno's Appointment

HeartBeam Inc. has appointed its Chief Executive Officer Robert Eno to the company's Board of Directors, expanding the board from eight to nine members. Eno, who became CEO in October 2024 after serving as president since January 2023, brings over three decades of medical technology leadership experience to the role.

The appointment comes at a critical juncture for HeartBeam, which is preparing to launch its groundbreaking 3D ECG technology pending FDA clearance of its 12-lead ECG synthesis software. Eno's extensive background in launching disruptive technologies could prove pivotal in the company's strategic positioning and potential market penetration.

HeartBeam's innovative platform aims to revolutionize cardiac care by developing a cable-free 12-lead ECG device capable of capturing heart electrical signals in three dimensions. This technology could significantly transform how cardiac health is monitored, enabling physicians to identify health trends and acute conditions outside traditional medical facilities.

With 13 U.S. and 4 international patents related to its technology, HeartBeam is positioning itself as a potential leader in portable cardiac diagnostic solutions. Eno's board appointment suggests the company is strategically aligning its leadership to support its ambitious technological and commercial objectives.